Cosmo Bio CompanyLimited (3386) Stock Overview
Engages in the purchase and sale of research reagents, equipment, and contract services related to life science worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
+ 1 more risk
3386 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Cosmo Bio Company,Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥1,370.00 |
| 52 Week High | JP¥1,486.00 |
| 52 Week Low | JP¥971.00 |
| Beta | 0.085 |
| 1 Month Change | 22.65% |
| 3 Month Change | 13.98% |
| 1 Year Change | 18.10% |
| 3 Year Change | 34.45% |
| 5 Year Change | 19.65% |
| Change since IPO | -32.51% |
Recent News & Updates
Cosmo Bio Company,Limited (TSE:3386) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected
Dec 04
Returns On Capital Signal Tricky Times Ahead For Cosmo Bio CompanyLimited (TSE:3386)
Nov 14Recent updates
Cosmo Bio Company,Limited (TSE:3386) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected
Dec 04Returns On Capital Signal Tricky Times Ahead For Cosmo Bio CompanyLimited (TSE:3386)
Nov 14We Think You Can Look Beyond Cosmo Bio CompanyLimited's (TSE:3386) Lackluster Earnings
Aug 12Cosmo Bio Company,Limited's (TSE:3386) Popularity With Investors Is Under Threat From Overpricing
Apr 15Cosmo Bio CompanyLimited's (TSE:3386) Shareholders Have More To Worry About Than Only Soft Earnings
Aug 12Cosmo Bio CompanyLimited (TYO:3386) Is Experiencing Growth In Returns On Capital
May 09Cosmo Bio Company,Limited (TYO:3386) Vies For A Place In Your Dividend Portfolio: Here's Why
Mar 23Cosmo Bio Company,Limited's (TYO:3386) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
Mar 02Will The ROCE Trend At Cosmo Bio CompanyLimited (TYO:3386) Continue?
Feb 07
Does Cosmo Bio CompanyLimited's (TYO:3386) Share Price Gain of 30% Match Its Business Performance?
Jan 17Should Cosmo Bio Company,Limited (TYO:3386) Be Part Of Your Dividend Portfolio?
Dec 23Do Fundamentals Have Any Role To Play In Driving Cosmo Bio Company,Limited's (TYO:3386) Stock Up Recently?
Dec 02Shareholder Returns
| 3386 | JP Healthcare | JP Market | |
|---|---|---|---|
| 7D | -1.4% | 0.5% | 1.3% |
| 1Y | 18.1% | 11.6% | 22.5% |
Return vs Industry: 3386 exceeded the JP Healthcare industry which returned 10.9% over the past year.
Return vs Market: 3386 underperformed the JP Market which returned 22.7% over the past year.
Price Volatility
| 3386 volatility | |
|---|---|
| 3386 Average Weekly Movement | 7.6% |
| Healthcare Industry Average Movement | 3.7% |
| Market Average Movement | 3.8% |
| 10% most volatile stocks in JP Market | 8.1% |
| 10% least volatile stocks in JP Market | 2.0% |
Stable Share Price: 3386's share price has been volatile over the past 3 months compared to the JP market.
Volatility Over Time: 3386's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of JP stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1978 | 174 | Norihiko Shibayama | www.cosmobio.co.jp |
Cosmo Bio Company,Limited, together with its subsidiaries, engages in the purchase and sale of research reagents, equipment, and contract services related to life science worldwide. The company distributes antibodies, antigens, biologically active substances, enzymes, substrates, peptides, amino acids, chemicals, carbohydrates, lipids, virus components, and bacteria, as well as detection reagents, cell and tissue culture systems, and gene analysis systems; and research instruments, including electrophoresis apparatuses, cell culture labware, gene manipulation systems, and data analysis software. It also provides drug discovery and custom research services; clinical diagnostics; consigned services, such as intestinal flora analysis, tear fluid analysis, and cell assays services; and custom peptide synthesis and antibody production services.
Cosmo Bio Company,Limited Fundamentals Summary
| 3386 fundamental statistics | |
|---|---|
| Market cap | JP¥7.77b |
| Earnings (TTM) | JP¥243.00m |
| Revenue (TTM) | JP¥10.51b |
Is 3386 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 3386 income statement (TTM) | |
|---|---|
| Revenue | JP¥10.51b |
| Cost of Revenue | JP¥6.92b |
| Gross Profit | JP¥3.60b |
| Other Expenses | JP¥3.35b |
| Earnings | JP¥243.00m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
Feb 13, 2026
| Earnings per share (EPS) | 42.82 |
| Gross Margin | 34.20% |
| Net Profit Margin | 2.31% |
| Debt/Equity Ratio | 0.2% |
How did 3386 perform over the long term?
See historical performance and comparisonDividends
Does 3386 pay a reliable dividends?
See 3386 dividend history and benchmarks| Cosmo Bio CompanyLimited dividend dates | |
|---|---|
| Ex Dividend Date | Dec 29 2025 |
| Dividend Pay Date | Mar 26 2026 |
| Days until Ex dividend | 19 days |
| Days until Dividend pay date | 106 days |
Does 3386 pay a reliable dividends?
See 3386 dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/09 08:17 |
| End of Day Share Price | 2025/12/09 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Cosmo Bio Company,Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.